Non-communicable disease patients who are active smoking Vernonia Cinerea lozenge non-communicable diseases Smoking cessation
Conditions
Interventions
All ingredients are similar to intervention lozenge except no Vernonia cinerea extract.,Vernonia cinerea extract 450 mg.
Placebo lozenge,Vernonia cinerea lozenge
Sponsors
TOBACCO CONTROL RESEARCH AND KNOWLEDGE MANAGEMENT CENTER
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Age at least 18 years old - Have at least 1 underlying non-communicable disease include hypertension, diabetes, dyslipidemia, cardiovascular diseases, cerebrovascular diseases, stable asthma, COPD stage A-C according to GOLD guideline, chronic kidney diseases - Smoke 10 cigarettes or over per day at least 1 month prior to study - Desired to quit smoking - Consent to participate in study
Exclusion criteria
Exclusion criteria: - Renal dysfunction (GFR < 30 ml/mins/1.73m2) - Liver dysfunction (Child-Pugh score C) - Hyperkalemia (serum potassium <=5 mEq/L) - Documented of active depression or psychosis - Active cancer - History of acute coronary syndrome in previous 4 weeks - Known case of pregnancy or lactation - Use other tobacco products or other addictive substances except alcohol - Use other smoking cessation drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| continuous abstinence rate 1 and 3 months after quit date Stop smoking is defined by self-reported on smoking cessation plus exhaled CO measurement | — |
Secondary
| Measure | Time frame |
|---|---|
| continuous abstinence rate (CAR) and point prevalence rate (PAR) 1,3, 6 and 12 months Stop smoking is defined by self-reported on smoking cessation plus exhaled CO measurement | — |
Countries
Thailand
Contacts
Public ContactKrittin Bunditanukul
Faculty of Pharmaceutical Science, Chulalongkorn University
Outcome results
None listed